SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated (SBC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
sbc · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$15.00
Consensus
$12.00
+302.7% upside
Low
$9.00
Median: $12 · Last Close: $2.98
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$12.00
302.7% upside
High Target
$15
403.4%
Low Target
$9
202.0%
Current Price
$2.98
as of today
Based on analyst price targets, the SBC stock price prediction for the next 12 months ranges from $9 to $15. The consensus SBC price forecast of $12.00 implies 302.7% upside from the current price of $2.98.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.95 | ↓ 1.08% |
1-day model range: $2.93–$2.97. Peak: $2.97 (-1.08%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -39.3% |
| 2028 | $1 | -52.4% |
| 2029 | $1 | -58.1% |
| 2030 | $1 | -60.8% |
| 2031 | — | -62.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SBC · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|
Wall Street analysts have recently issued updated ratings on SBC Medical Group Holdings Incorporated (SBC) stock. Of the recent 0 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover SBC.
Analyst Recommendation Trends
SBC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$218M
↑ 20.3% YoY
Revenue Next Year
$179M
↓ 17.6% YoY
EPS This Year
$0.59
EPS Next Year
$0.46
↓ 22.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast SBC EPS of $0.59 for the current fiscal year, based on estimates from 2 analysts. The SBC revenue forecast is $218M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SBC stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SBC price target is $12.00 (+302.7% upside), with an analyst consensus of Buy.
The SBC short-term stock prediction for tomorrow is $2.95 (-1.08%). The SBC stock price prediction for 2027 estimates an average of $2. The SBC stock prediction for 2030 projects a range of $1–$1.
SBC Medical Group Holdings Incorporated trades on NASDAQ under the ticker SBC. The SBC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
SBC forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month SBC price target is $12.00, with a high forecast of $15.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies +302.7% potential upside from the current price of $2.98.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.